Triprolidine: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: February 27, 2026🚩 Report this page

Triprolidine

Other Antihistamines For Systemic Use

GB MHRA

Drug class: Other Antihistamines For Systemic Use
Availability: See label
Markets covered: 1
Products on record: 1

R06AXOther Antihistamines For Systemic Use

Overview

Triprolidine is an active pharmaceutical ingredient in the Other Antihistamines For Systemic Use group (R06AX). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	1	February 27, 2026

GBUnited Kingdom· MHRA

1 product

Uses

GBOfficial regulatory label· revised February 27, 2026[1]

For the symptomatic relief of upper respiratory tract disorders which are benefited by a combination of a nasal decongestant and histamine H1-receptor antagonist, for example: Allergic Rhinitis Vasomotor Rhinitis The Common Cold and Influenza

How to take

Drug interactions

Known interactions involving Triprolidine. Select one for details. This list is informational and not a complete interaction checker.

Potassium Chloride Potassium Citrate Propoxyphene Topiramate Zonisamide Acetylcholine Aclidinium Acrivastine Alfentanil Alprazolam Amantadine Amitriptyline Amobarbital Amoxapine Apomorphine Apraclonidine Aripiprazole Asenapine Atropine Azatadine Azelastine Baclofen Benzhydrocodone Biperiden Botulinum Toxin Type A Botulinum Toxin Type B Brexanolone Brexpiprazole Brimonidine Brivaracetam Bromocriptine Brompheniramine Buprenorphine Buspirone Butabarbital Butalbital Butorphanol Candida Albicans Cannabidiol Carbamazepine Carbamoylcholine Carbinoxamine Cariprazine Carisoprodol Cenobamate Cetirizine Chlorcyclizine Chlordiazepoxide Chlormezanone Chlorphenesin Chlorpheniramine Chlorpromazine Chlorzoxazone Citalopram Clemastine Clidinium Clobazam Clomipramine Clonazepam Clonidine Clorazepate Clozapine Coccidioides Immitis Spherule Codeine Cyclizine Cyclobenzaprine Cyproheptadine Dantrolene Darifenacin Demecarium Desipramine Desvenlafaxine Deutetrabenazine Dexbrompheniramine Dexmedetomidine Dextromethorphan Dezocine Diazepam Dichloralphenazone Dicyclomine Dihydrocodeine Dimenhydrinate Diphenhydramine Disopyramide Donepezil Doxepin Doxylamine Dronabinol Droperidol Duloxetine Eluxadoline Entacapone Escitalopram Esketamine Eslicarbazepine Estazolam Eszopiclone Ethanol Ethosuximide Ethotoin Ezogabine Felbamate Fentanyl Fesoterodine Flavoxate Flibanserin Fluoxetine Fluphenazine Flurazepam Fluvoxamine Fosphenytoin Gabapentin Galantamine Glycopyrronium Halazepam Haloperidol Histamine Hydrocodone Hydromorphone Hydroxyzine Hyoscyamine Ifosfamide Iloperidone Imipramine Ipratropium Isocarboxazid Isoflurophate Ketamine Lamotrigine Lasmiditan Lemborexant Levetiracetam Levocetirizine Levorphanol Linezolid Lithium Carbonate Lofexidine Loperamide Lorazepam Loxapine Lumateperone Lurasidone Maprotiline Meclizine Memantine Mepenzolate Meperidine Mephenytoin Mephobarbital Meprobamate Mesoridazine Metaxalone Methadone Methdilazine Methocarbamol Methotrimeprazine Methscopolamine Methsuximide Metoclopramide Metyrosine Midazolam Mirtazapine Molindone Morphine Nabilone Nalbuphine Nefazodone Nortriptyline Olanzapine Oliceridine Olopatadine Opicapone Opium Orphenadrine Oxazepam Oxcarbazepine Oxybutynin Oxycodone Oxymorphone Paliperidone Paraldehyde Paramethadione Paroxetine Pentazocine Pentobarbital Perampanel Pergolide Perphenazine Phenacemide Phenelzine Phenindamine Phenobarbital Phensuximide Phenyltoloxamine Phenytoin Physostigmine Pilocarpine Pimozide Pitolisant Pramipexole Pregabalin Primidone Procarbazine Prochlorperazine Procyclidine Promazine Promethazine Propantheline Propiomazine Protriptyline Pyrilamine Quazepam Quetiapine Ramelteon Rasagiline Remifentanil Remimazolam Revefenacin Risperidone Rivastigmine Ropinirole Rotigotine Rufinamide Scopolamine Secobarbital Sertraline Sibutramine Solifenacin Stiripentol Sufentanil Suvorexant Tacrine Tapentadol Tasimelteon Temazepam Tetrabenazine Thalidomide Thiethylperazine Thioridazine Thiothixene

Showing 240 of 267. Type above to find a specific drug.

Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.

Sources & citations

[1]MHRA (UK) · PL155130014 · revised February 27, 2026

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised February 27, 2026[1]

Placebo-controlled studies with sufficient adverse event data are not available for the combination of pseudoephedrine and triprolidine. Adverse drug reactions identified during clinical trials and post-marketing experience with pseudoephedrine, triprolidine or the combination are listed below by System Organ Class (SOC).
The frequencies are defined according to the following convention:
Very common ≥1/10 Common ≥1/100 and < 1/10 Uncommon ≥1/1,000 and <1/100 Rare ≥1/10,000 and <1/1,000 Very rare <1/10,000 Not known (cannot be estimated from the available data) ADRs are presented by frequency category based on 1) incidence in adequately designed clinical trials or epidemiology studies, if available, or 2) when incidence cannot be estimated, frequency category is listed as ‘Not known.
4) Psychomotor hyperactivity Very common Common Common Common Common Rare Rare Rare Not Known Not Known Not Known Not Known Vision blurred CommonEye Disorders Ischaemic optic neuropathy Not Known Cardiac Disorders Palpitations Dysrhythmias Myocardial infarction / myocardial ischaemia Tachycardia Rare Not Known Not Known Not Known Vascular Disorders Hypotension Hypertension Rare Not Known Respiratory, Thoracic and Mediastinal Disorders Increased viscosity of bronchial secretion Dry throat Epistaxis Nasal dryness Common Not known Not known Not known Gastrointestinal Disorders Dry mouth Gastrointestinal disorder Nausea Abdominal discomfort Ischaemic colitis Vomiting Common Common Common Not Known Not Known Not Known Hepatobiliary Disorders Liver Disorder Rare Skin and Subcutaneous Tissue Disorders Angioedema Pruritus Rash Severe skin reactions, including acute generalised exanthematous pustulosis (AGEP) Urticaria Not known Not known Not known Not known Not known Renal and Urinary Disorders Urinary Retention (in men whom prostatic enlargement could have been an important predisposing factor) Dysuria Common Not known General Disorders and Administration Site Conditions Fatigue Not known Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorization of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

GBOfficial regulatory label· Warnings and precautions· revised February 27, 2026[1]

Multi-Action ACTIFED Tablets may cause drowsiness. This product should not be used to sedate a child. Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, sedatives and tranquilisers.
While taking Multi-Action ACTIFED Tablets, patients should be advised to avoid alcoholic beverages and consult a healthcare professional prior to taking with central nervous system depressants. Use with caution in prostatic hypertrophy, urinary retention or susceptibility to angle closure.
Patients with thyroid disease who are receiving thyroid hormones are advised to consult a physician before using this product. Use with caution in occlusive vascular disease. If any of the following occur, this product should be stopped.
Hallucinations Restlessness Sleep disturbances Severe Skin Reactions:
Severe skin reactions such as acute generalized exanthematous pustulosis (AGEP) may occur with pseudoephedrine-containing products. This acute pustular eruption may occur within the first 2 days of treatment, with fever, and numerous, small, mostly non-follicular pustules arising on a widespread oedematous erythema and mainly localized on the skin folds, trunk, and upper extremities.
Patients should be carefully monitored. If signs and symptoms such as pyrexia, erythema, or many small pustules are observed, administration of this medicine should be discontinued, and appropriate measures taken if needed.
Ischaemic colitis:
Some cases of ischaemic colitis have been reported with pseudoephedrine. Pseudoephedrine should be discontinued, and medical advice sought if sudden abdominal pain, rectal bleeding or other symptoms of ischaemic colitis develop.
Ischaemic optic neuropathy:
Cases of ischaemic optic neuropathy have been reported with pseudoephedrine. Pseudoephedrine should be discontinued if sudden loss of vision or decreased visual acuity such as scotoma occurs. 8). 3). Pseudoephedrine should be discontinued and immediate medical assistance sought if the following symptoms occur: sudden severe headache or thunderclap headache, nausea, vomiting, confusion, seizures and/or visual disturbances.

This is not medical advice. Consult a qualified healthcare professional.

Overview

Regulatory status by market

GBUnited Kingdom· MHRA

Drug interactions

Drugs in the same class

Sources & citations